MBX Posts $62.4M Q3 Loss; $481.6M Cash Funds Runway Into 2029
MBX has more than doubled off its 52-week low of $21.9.
Summary
MBX reported a $62.4M Q3 2026 net loss, inflated by $20.8M of former-CEO stock comp, while holding $481.6M in cash that funds operations into 2029. The Phase 3 hypoparathyroidism trial is enrolling and 12-week obesity data for MBX 4291 is due in Q4 2026.
Key Events · Earnings and Guidance · MBX
-
Q3 Net Loss Widens to $62.4M
Net loss was $62.4M versus $21.6M in Q3 2025, with loss per share of $1.29 versus $0.63.
-
Cash Runway Extended Into 2029
Cash, cash equivalents and marketable securities totaled $481.6M at September 30, 2026, including $97.6M of net ATM proceeds during the quarter.
-
Former-CEO Stock Comp Drives G&A
G&A rose to $34.3M from $4.7M, including $20.8M of stock-based compensation from modifying the former chief executive officer's awards.
-
Phase 3 Enrollment Underway
The pivotal Phase 3 oPTimize trial of once-weekly canvuparatide in chronic hypoparathyroidism is enrolling roughly 160 adults after first patient dosing in August 2026.
Analysis · MBX · Life Sciences
The quarter's headline is the swing to a $62.4M net loss from $21.6M a year ago, but most of the damage is accounting, not cash burn: G&A jumped to $34.3M largely on $20.8M of stock-based compensation tied to modifying the former CEO's awards, and R&D rose to $32.0M as the canvuparatide Phase 3 oPTimize trial started. The balance sheet is the real story — $481.6M in cash after $97.6M of ATM proceeds keeps funding through 2029, so the Phase 3 readout and the Q4 2026 MBX 4291 12-week MAD obesity data are financed without another raise. That removes near-term financing risk, which is why this matters more than a routine quarterly print.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBX was trading at $53.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $21.90 to $72.64. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.